Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  MEDNAX, Inc.    MD

MEDNAX, INC.

(MD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

MEDNAX, Inc. : After the gains, a correction ?

share with twitter share with LinkedIn share with facebook
07/30/2020 | 09:52am EDT
short sell
Stop-loss triggered
Entry price : 19.58$ | Target : 15.1$ | Stop-loss : 21.5$ | Potential : 22.88%
MEDNAX, Inc. shares could experience selling pressure following the strong increase in its stock price. Over the short term, the stock in fact displays first signs of exhaustion.
Investors should open a short trade and target the $ 15.1.
MEDNAX, Inc. : MEDNAX, Inc. : After the gains, a correction ?
Summary
  • The company usually posts poor financials for mid or long term investments.

Weaknesses
  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • Low profitability weakens the company.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 45.77 times its estimated earnings per share for the ongoing year.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.

David Meurisse
© MarketScreener.com 2020
share with twitter share with LinkedIn share with facebook

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2020 2 394 M - -
Net income 2020 -636 M - -
Net Debt 2020 1 302 M - -
P/E ratio 2020 -2,66x
Yield 2020 -
Capitalization 1 668 M 1 668 M -
EV / Sales 2020 1,24x
EV / Sales 2021 1,30x
Nbr of Employees 9 480
Free-Float 95,5%
Upcoming event on MEDNAX, INC.
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 19,73 $
Last Close Price 19,92 $
Spread / Highest target 25,5%
Spread / Average Target -0,97%
Spread / Lowest Target -44,8%
EPS Revisions
Managers
NameTitle
Mark S. Ordan Chief Executive Officer & Director
Guy P. Sansone Chairman
Stephen D. Farber Chief Financial Officer & Executive Vice President
Tony Ambegaoker Chief Information Officer
Roger J. Medel Director
Sector and Competitors
1st jan.Capitalization (M$)
MEDNAX, INC.-28.32%1 700
CVS HEALTH CORPORATION-12.52%85 053
HCA HEALTHCARE, INC.-10.61%44 664
FRESENIUS MEDICAL CARE AG & CO. KGAA12.01%25 435
LABORATORY CORPORATION OF AMERICA HOLDINGS11.19%18 321
QUEST DIAGNOSTICS13.45%16 271